Morning. watching NEOT for bounce play maybe. -70% 08:17 AM EDT, 06/26/2017 (MT Newswires) -- Neothetics (NEOT) was due off a trading halt at 8:30 am ET. The company said top-line safety and efficacy results from its phase 2 proof-of-concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat did not demonstrate improvement on any efficacy measurements or separation from placebo.
LIPO-202 continued to show a benign safety profile.
The study endpoints included both safety and efficacy measurements. Efficacy measures assessed improvement in the subject's submental region as evaluated by both the patient and clinician, covering overall subject satisfaction and evaluation of submental fat thickness by calipers.
============================================================
